Latent Labs

AI-first drug design built on AlphaFold for pharma R&D.

Isomorphic Labs is an AI-first drug discovery company spun out of Google DeepMind, building generative and predictive ML models for molecular design and drug-performance prediction. Its Drug Design Engine builds on AlphaFold to advance internal and partnered pipelines with Eli Lilly, Novartis, and J&J. It is a drug-discovery company that works through pharma R&D partnerships rather than a self-serve product.

Foundation models for molecular structure and antibody design.

Chai Discovery builds foundation models for drug discovery — Chai-1 for biomolecular structure prediction across proteins, ligands, DNA/RNA, and glycans, and Chai-2 for de novo antibody design. Chai-1 weights and inference code are released for non-commercial use, and a free web server runs the model in-browser. It is both a model provider and a usable platform.

Generative protein language models that design novel proteins.

Profluent uses generative AI — its ProGen-lineage protein language models — to author novel proteins from scratch or from natural scaffolds, for medicine and agriculture. It released OpenCRISPR-1, described as the first AI-designed gene editor (open-licensed and published in Nature), and is expanding into antibodies and enzymes. It operates as an AI protein-design company working through partnerships with open-sequence releases, not a self-serve consumer platform.

Frontier protein language models (the ESM family) for biology.

EvolutionaryScale builds frontier protein language models — the ESM family, including ESM3, which reasons jointly over sequence, structure, and function. ESM3-open ships open weights and code under a non-commercial license, while larger models are served via its Forge API and AWS/NVIDIA partnerships. It is both an open-model provider and an API platform for protein design and understanding.